The trial narrowly missed statistical significance for its primary endpoint of a composite of total hospitalizations for HF and death from cardiovascular causes ( Solomon et al., 2019 ).
← all excerpts
Dapagliflozin <i>versus</i> sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction.
1
—
—